Oxidative metabolism of endocannabinoids by COX-2

Current Pharmaceutical Design

Volumn 10, Issue 6, 2004, Pages 659-667

  Kozak, Kevin R ^a   Prusakiewicz, Jeffery J ^a   Marnett, Lawrence J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; ARACHIDONATE 15 LIPOXYGENASE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FATTY ACID AMIDASE; FLURBIPROFEN; ICOSANOID; INDOMETACIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROSTACYCLIN; PROSTAGLANDIN A2; PROSTAGLANDIN B2; PROSTAGLANDIN D SYNTHASE; PROSTAGLANDIN D2; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN E2 DERIVATIVE; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN H2; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; THROMBOXANE SYNTHASE; UNINDEXED DRUG;

AEROBIC METABOLISM; ANTINOCICEPTION; BIOCHEMISTRY; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME SPECIFICITY; ENZYME STRUCTURE; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; OXYGENATION; PRIORITY JOURNAL; PROTEIN HYDROLYSIS; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

BINDING SITES; CYCLOOXYGENASE 2; ENDOCANNABINOIDS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; OXIDATION-REDUCTION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SIGNAL TRANSDUCTION;

EID: 1442326013     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043453081     Document Type: Review

References (64)

1. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990; 265: 16737-40.
2. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88: 2692-6.
3. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991; 266: 12866-72.
4. O'Banion MK, Sadowski HB, Winn V, Young DA. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991; 266: 23261-7.
5. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993; 330: 156-60.
6. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Isakson P. Distribution of COX-1 and COX-2 in normal and inflamed tissues. Adv Exp Med Biol 1997; 400A: 167-70.
7. Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta 1996; 1299: 125-40.
8. Picot D, Loll PJ, Garavito RM. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994; 367: 243-9.
9. Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol 1996; 3: 927-33.
10. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996; 384: 644-8.
11. Kozak KR, Prusakiewicz JJ, Rowlinson SW, Schneider C, Marnett LJ. Amino acid determinants in cyclooxygenase-2 oxygenation of the endocannabinoid 2-arachidonylglycerol. J Biol Chem 2001; 276: 30072-7.
12. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000; 69: 145-82.
13. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-4.
14. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-9.
15. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-5.
16. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al. 2-Arachidonylglycerol: a possible endogenous cannabinoid receptor ligand in brain: Biochem Biophys Res Commun 1995; 215: 89-97.
17. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 83-90.
18. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 2001; 98: 3662-5.
19. Maccarrone M, Falciglia K, Di Rienzo M, Finazzi-Agro A. Endocannabinoids, hormone-cytokine networks and human fertility. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 309-17.
20. Wenger T, Moldrich G. The role of endocannabinoids in the hypothalamic regulation of visceral function. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 301-7.
21. Lichtman AH, Varvel SA, Martin BR. Endocannabinoids in cognition and dependence. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 269-85.
22. Fernandez-Ruiz J, Lastres-Becker I, Cabranes A, Gonzalez S, Ramos JA. Endocannabinoids and basal ganglia functionality. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 257-67.
23. Walker JM, Huang SM. Endocannabinoids in pain modulation. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 235-42.
24. Hogestatt ED, Zygmunt PM. Cardiovascular pharmacology of anandamide. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 343-51.
25. Pinto L, Capasso R, Di Carlo G, Izzo AA. Endocannabinoids and the gut. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 333-41.
26. Parolaro D, Massi P, Rubino T, Monti E. Endocannabinoids in the immune system and cancer. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 319-32.
27. Lands WE, Samuelsson B. Phospholipid precursors of prostaglandins. Biochim Biophys Acta 1968; 164: 426-9.
28. Vonkeman H, van Dorp DA. The action of prostaglandin synthetase on 2-arachidonyl-lecithin. Biochim Biophys Acta 1968; 164: 430-2.
29. 2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem 1997; 272: 21181-6.
30. So OY, Scarafia LE, Mak AY, Callan OH, Swinney DC. The dynamics of prostaglandin H synthases. J Biol Chem 1998; 273: 5801-7.
31. Kozak KR, Prusakiewicz JJ, Rowlinson SW, Prudhomme DR, Marnett LJ. Amino acid determinants in cyclooxygenase-2 oxygenation of the endocannabinoid, anandamide. Biochemistry 2003; 42: 9041-9.
32. Di Marzo V. Biosynthesis and inactivation of endocannabinoids: relevance to their proposed role as neuromodulators. Life Sci 1999; 65: 645-55.
33. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997; 388: 773-8.
34. Bisogno T, Berrendero F, Ambrosino G, Cebeira M, Ramos JA, Fernandez-Ruiz JJ, et al. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem Biophys Res Commun 1999; 256, 377-80.
35. Koga D, Santa T, Fukushima T, Homma H, Imai K. Liquid chromatographic-atmospheric pressure chemical ionization mass spectrometric determination of anandamide and its analogs in rat brain and peripheral tissues. J Chromatogr B 1997; 690: 7-13.
36. Schmid PC, Paria BC, Krebsbach RJ, Schmid HHO, Dey SK. Changes in anandamide levels in mouse uterus are associated with uterine receptivity for embryo implantation. Proc Natl Acad Sci USA 1997; 94: 4188-92.
37. Goparaju SK, Ueda N, Yamguchi H, Yamamoto S. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett 1998; 422: 69-73.
38. Maccarrone M, van der Stelt M, Rossi A, Veldink GA, Vliegenthart JF, Agro AF. Anandamide hydrolysis by human cells in culture and brain. J Biol Chem 1998; 273: 32332-9.
39. Lang W, Qin C, Lin S, Khanolkar AD, Goutopoulos A, Fan P, et al. Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. J Med Chem 1999; 42: 896-902.
40. Desarnaud F, Cadas H, Piomelli D. Anandamide amidohydrolase activity in rat brain microsomes. J Biol Chem 1995; 270: 6030-5.
41. Ueda N, Kurahashi Y, Yamamoto S, Tokunaga T. Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide. J Biol Chem 1995; 270: 23823-7.
42. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001; 98: 9371-6.
43. Kozak KR, Rowlinson SW, Marnett LJ. Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J Biol Chem 2000; 275: 33744-9.
44. Kozak KR, Prusakiewicz JJ, Rowlinson SW, Schneider C, Marnett LJ. Amino acid determinants in cyclooxygenase-2 oxygenation of the endocannabinoid 2-arachidonylglycerol. J Biol Chem 2001; 276: 30072-7.
45. Kozak KR, Crews BC, Morrow JD, Wang LH, Ma YH, Weinander R, et al. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J. Biol. Chem 2002; 277: 44877-85.
46. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366-72.
47. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96: 272-7.
48. Pinto JC, Potie F, Rice KC, Boring D, Johnson MR, Evans DM, et al. Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid. Mol Pharmacol 1994; 46: 516-22.
49. Guhring H, Hamza M, Sergejeva M, Ates M, Kotalla CE, Ledent C, et al. A role for endocannabinoids in indomethacin-induced spinal antinociception. Eur J Pharmacol 2002; 454: 153-63.
50. Ates M, Hamza M, Seidel K, Kotalla CE, Ledent C, Guhring H. Intrathecally applied flurbiprofen produces an endocannabinoid-dependent antinociception in the rat formalin test. Eur J Neurosci 2003; 17: 597-604.
51. Samuelsson B, Granstrom E, Green K, Hamberg M. Metabolism of prostaglandins. Ann N Y Acad Sci 1971; 180: 138-63.
52. Samuelsson B, Goldyne M, Granstrom E, Hamberg M, Hammarstrom S, Malmsten C. Prostaglandins and thromboxanes. Annu Rev Biochem 1978; 47: 997-1029.
53. Kozak KR, Crews BC, Ray JL, Tai HH, Morrow JD, Marnett LJ. Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo. J Biol Chem 2001; 276: 36993-8.
54. Davies SS, Ju WK, Neufeld AH, Abran D, Chemtob S, Roberts LJ 2nd. Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. J Ocul Pharmacol Ther 2003; 19: 45-54.
55. Maxey KM, Johnson JL, LaBrecque J. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol 2002; 47 Suppl 1: S34-40.
56. Woodward DF, Krauss AH, Chen J, Liang Y, Li C, Protzman CE, et al. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J Pharmacol Exp Ther 2003; 305: 772-85.
57. Zhao X, Pearson KE, Stephan DA, Russell P. Effects of prostaglandin analogues on human ciliary muscle and trabecular meshwork cells. Invest Ophthalmol Vis Sci 2003; 44: 1945-52.
58. Ross RA, Craib SJ, Stevenson LA, Pertwee RG, Henderson A, Toole J, et al. Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide. J Pharmacol Exp Ther 2002; 301: 900-7.
59. Kozak KR, Gupta RA, Moody JS, Ji C, Boeglin WE, DuBois RN, et al. 15-Lipoxygenase metabolism of 2-arachidonylglycerol. Generation of a peroxisome proliferator-activated receptor alpha agonist. J Biol Chem 2002; 277: 23278-86.
60. Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C, et al. Interleukin-4-dependent production of PPAR-gamma ligands; in macrophages by 12/15-lipoxygenase. Nature 1999; 400: 378-82.
61. Shappell SB, Gupta RA, Manning S, Whitehead R, Boeglin WE, Schneider C, et al. 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res 2001; 61: 497-503.
62. Bisogno T, De Petrocellis L, Di Marzo V. Fatty acid amide hydrolase an enzyme with many bioactive substrates. Possible therapeutic implications. Curr Pharm Design 2002; 8(7): 533-47.
63. Hawkey CJ, Skelly MM. Gastrointestinal safety of selective COX-2 inhibitors. Curr Pharm Design 2002; 8(12): 1077-89.
64. Takeuchi K, Tanaka A, Suzuki K, Mizoguchi H. Gastrointestinal sparing anti-inflammatory drugs - effects on ulcerogenic and healing responses. Curr Pharm Design 2001; 7(1): 49-69.